Factors Influencing a Specific Pathologic Diagnosis of Non-Small-Cell Lung Carcinoma

被引:6
|
作者
Sulpher, Jeffrey A. [1 ]
Owen, Scott P. [2 ]
Hon, Henrique [2 ]
Tobros, Kimberly [2 ]
Shepherd, Frances A. [2 ]
Sabri, Elham [3 ]
Gomes, Marcio [4 ]
Sekhon, Harman [4 ]
Liu, Geoffrey [2 ]
Canil, Christina M. [1 ]
Wheatley-Price, Paul [1 ]
机构
[1] Univ Ottawa, Dept Med, Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[2] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Div Med Oncol & Hematol,Dept Med, Toronto, ON M5S 1A1, Canada
[3] Univ Ottawa, Res Inst, Ottawa Hosp, Ottawa, ON, Canada
[4] Univ Ottawa, Dept Pathol & Lab Med, Ottawa Hosp, Ottawa, ON, Canada
关键词
Chart review; Diagnosis; Histology; Non-small-cell lung cancer; CANCER; CHEMOTHERAPY; MUTATIONS; GEFITINIB; CYTOLOGY; EGFR; ADENOCARCINOMA; CLASSIFICATION; CARBOPLATIN; PACLITAXEL;
D O I
10.1016/j.cllc.2012.11.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pathologic subtyping of non-small-cell lung carcinoma is increasingly important when selecting therapy. The records of 739 patients were reviewed to identify factors associated with attaining a specific pathologic diagnosis. Only 456 (62%) of patients received a specific pathologic diagnosis, which was significantly associated with histologic biopsy samples, immunohistochemical testing, and diagnosis outside of an academic center. Introduction: Historically, a non-small-cell lung carcinoma diagnosis, without pathologic subclassification, provided sufficient information to guide therapy. Evidence now demonstrates that pathologic subtype classification is central in selecting optimal treatment. This review aimed to identify factors associated with a specific pathologic diagnosis. Methods: All nonoperative cases of non-small-cell lung carcinoma (NSCLC) referred to the medical oncology divisions of the Ottawa Hospital Cancer Centre (2008) and Princess Margaret Hospital, Toronto (2007-2010) were identified. The charts were reviewed for demographics, diagnostic methods, and final diagnosis. Logistic regression was performed to identify variables associated with a specific diagnosis. Results: Of 739 patient records analyzed, 377 (51%) were men, 299 (40%) were aged over 70 years, and 510 (69%) had an Eastern Cooperative Oncology Group performance status of 0-2. Three hundred and eighty five (52%) of patients were diagnosed in a tertiary academic center. The lung primary was sampled in 503 (68%) of patients. Computed tomography-guided biopsy (n = 370, 50%) and bronchoscopy (n = 179, 24%) were the most common techniques. Four hundred and seventy seven (65%) of biopsies were cytologic specimens alone, and immunohistochemistry was performed in 337 (46%) of cases. The most common diagnoses were adenocarcinoma (n = 338, 46%), NSCLC not otherwise specified (n = 254, 34%), and squamous cell carcinoma (n = 115, 16%). Overall, 456 (62%) of patients received a specific pathologic diagnosis. Factors significantly associated with attaining a specific pathologic diagnosis were diagnosis outside an academic center (adjusted odds ratios [OR] 2.1 [95% CI, 1.41-3.14]; P = .0003), histologic laboratory samples (adjusted OR 1.58 [95% CI, 1.003-2.49]; P = .049), and immunohistochemical testing (adjusted OR 1.82 [95% CI, 1.25-2.70], P = .0021). Conclusions: A significant minority of patients with NSCLC do not receive a specific pathologic diagnosis. In an era of individualized medicine, this may potentially impact optimal clinical management. Clinical Lung Cancer, Vol. 14, No. 3, 238-44 (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:238 / 244
页数:7
相关论文
共 50 条
  • [1] Non-Small-Cell Lung Carcinoma Interdisciplinary Diagnosis and Therapy
    Niederle, N.
    ONKOLOGE, 2011, 17 (08): : 667 - 668
  • [2] Factors influencing a specific histologic diagnosis of non-small cell lung cancer.
    Sulpher, J. A.
    Owen, S. P.
    Hon, H.
    Tobros, K.
    Shepherd, F. A.
    Sabri, E.
    Liu, G.
    Canil, C. M.
    Wheatley-Price, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Chemotherapy of non-small-cell lung carcinoma
    LeChevalier, T
    PRESSE MEDICALE, 1996, 25 (35): : 1699 - 1703
  • [4] PROGNOSTIC FACTORS IN THE TREATMENT OF NON-SMALL-CELL LUNG-CARCINOMA (NSCLC)
    BUSCH, M
    DOHMEN, T
    DUHMKE, E
    HUTTEMANN, U
    EUROPEAN RADIOLOGY, 1995, 5 (03) : 312 - 317
  • [5] Crizotinib in the treatment of non-small-cell lung carcinoma
    Pluzanski, Adam
    Piorek, Aleksandra
    Krzakowski, Maciej
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2012, 16 (06): : 480 - 484
  • [6] INTEGRIN EXPRESSION IN NON-SMALL-CELL CARCINOMA OF THE LUNG
    SMYTHE, WR
    LEBEL, E
    BAVARIA, JE
    KAISER, LR
    ALBELDA, SM
    CANCER AND METASTASIS REVIEWS, 1995, 14 (03) : 229 - 239
  • [7] Cetuximab and biomarkers in non-small-cell lung carcinoma
    Patil, Nitin
    Abba, Mohammed
    Allgayer, Heike
    BIOLOGICS-TARGETS & THERAPY, 2012, 6 : 221 - 231
  • [8] Targeted therapy of non-small-cell lung carcinoma
    Tiwari, Divya
    Brodie, Seth A.
    Brandes, Johann C.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2012, 6 (01) : 41 - 56
  • [9] CHEMOTHERAPY OF METASTATIC NON-SMALL-CELL CARCINOMA OF THE LUNG
    RUCKDESCHEL, JC
    HEMATOLOGICAL ONCOLOGY, 1992, 10 (01) : 25 - 30
  • [10] Pneumopericardium as a non-small-cell lung carcinoma complication
    Kubisa, Anna
    Lesinska, Anna
    Dec, Pawel
    Szewczak-Glodek, Malgorzata
    Kochanowski, Leszek
    Kubisa, Bartosz
    Feledyk, Grzegorz
    Czarnecka, Michalina
    Wojcik, Janusz
    Grodzki, Tomasz
    KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA, 2016, 13 (03): : 257 - 259